Chronic News and Research

RSS

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1 clinical study of ARC-520, the company's clinical candidate for the treatment of chronic hepatitis B infection, at the HepDART 2013 conference being held on The Big Island, Hawaii.

9 Dec 2013

MUC5B protein plays key role in many lung-related ailments

An international team of researchers has zeroed in on a protein that plays a key role in many lung-related ailments, from seasonal coughing and hacking to more serious diseases such as MRSA infections and cystic fibrosis.

9 Dec 2013

Increased inflammation in prostate may predict reduced risk for cancer

Doctors at the North Shore-LIJ Health System have discovered that increased inflammation in the prostate may predict reduced risk for prostate cancer. The findings are published online in CANCER.

9 Dec 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.

9 Dec 2013

Signs of inflammation in man’s prostate biopsy may indicate reduced risk

Signs of inflammation in a man’s prostate biopsy may indicate he has a reduced risk of subsequently being diagnosed with prostate cancer in a future biopsy. That’s the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

9 Dec 2013

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).

9 Dec 2013

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Novartis is highlighting new research from members of the faculty at the University of Pennsylvania’s Perelman School of Medicine on the investigational chimeric antigen receptor therapy, CTL019. Several studies being presented at the American Society of Hematology annual meeting add to the scientific understanding of CTL019 in the treatment of acute lymphoblastic leukemia and chronic lymphocytic leukemia and build on earlier research findings.

9 Dec 2013

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient's immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children's Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.

9 Dec 2013

Researchers identify central switch by which HDL controls inflammatory response

High-density lipoprotein, known colloquially as "good cholesterol", protects against dangerous deposits in the arteries. An important function of HDL is its anti-inflammatory properties. An international research team at the Institute of Innate Immunity at the University Hospital of Bonn and the LIMES Institute at the University of Bonn has identified a central switch by which HDL controls the inflammatory response. The results are presented in the current issue of "Nature Immunology".

9 Dec 2013

Revised Clinical Practice Guidelines on management of HCV published by EASL

The European Association for the Study of the Liver today publishes their revised Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection. The EASL guidelines, which supersede the previous version published in 2011, are designed to help physicians and other healthcare providers optimise their management of patients with acute and chronic HCV.

9 Dec 2013

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

9 Dec 2013

New study reports first evidence of specific molecular changes in the body with meditation

With evidence growing that meditation can have beneficial health effects, scientists have sought to understand how these practices physically affect the body.

6 Dec 2013

ZephyrLIFE remote monitoring system released for the growing market of transitional care

Zephyr Technology is proud to announce the release of ZephyrLIFE - the world's first remote monitoring system designed specifically for the growing market of transitional care. Transitional care involves managing the continuity of health care during the transition between health care practitioners and facilities as a patient's condition and care needs change during the course of a chronic or acute illness, which ZephyrLIFE has been designed for.

6 Dec 2013

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.

6 Dec 2013

ALS TDI forms research partnership with Neurimmune to advance potential treatments for ALS

The ALS Therapy Development Institute (ALS TDI), together with its wholly-owned subsidiary, Anelixis Therapeutics, announced today that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease.

6 Dec 2013

Low vitamin D levels: Not a cause but a consequence of ill health

A comprehensive review of the evidence suggests that low vitamin D levels are not a cause but a consequence of ill health, casting strong doubt on the value of vitamin D supplements to protect against acute and chronic disorders such as cancer, cardiovascular disease, diabetes, Parkinson’s disease, and even death.

6 Dec 2013

Scientists identify key factor for limiting inflammatory responses, particularly in skin

Sanford-Burnham scientists have identified the B and T Lymphocyte Attenuator (BTLA) inhibitory receptor as a key factor in limiting inflammatory responses, particularly in the skin. The study, published online today in Immunity, provides clarity on how T cells get fired up to protect against pathogens, and then cool down to restore immune homeostasis.

6 Dec 2013

Study validates prognostic tool that determines risk of death within 1 year of hospital admission

A University of Colorado Cancer Center study recently published in the Journal of Hospital Medicine validates a prognostic tool that determines risk of death within a year of hospital admission, helping doctors match treatments to patients' values and goals of care.

6 Dec 2013

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

metelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis a Mayo Clinic study has found. The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans.

6 Dec 2013

Chronic News and Research

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

MUC5B protein plays key role in many lung-related ailments

Increased inflammation in prostate may predict reduced risk for cancer

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Signs of inflammation in man’s prostate biopsy may indicate reduced risk

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Researchers identify central switch by which HDL controls inflammatory response

Revised Clinical Practice Guidelines on management of HCV published by EASL

Genetically engineered cell therapies demonstrate early efficacy, safety in patients with blood disorders

New study reports first evidence of specific molecular changes in the body with meditation

ZephyrLIFE remote monitoring system released for the growing market of transitional care

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

ALS TDI forms research partnership with Neurimmune to advance potential treatments for ALS

Low vitamin D levels: Not a cause but a consequence of ill health

Scientists identify key factor for limiting inflammatory responses, particularly in skin

Study validates prognostic tool that determines risk of death within 1 year of hospital admission

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

Industry Focus eBook - Cell biology (5th edition) eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News